RxDoctor Payments Data

Jennifer Whittington, APRN

Psychiatric/Mental Health · Richmond, KYNPI 1245853498

Payments from drug & device makers

$2,483in general payments, 2019–2025

Across 134 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$383
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$314
  • Johnson & Johnson$291
  • Ironshore Pharmaceuticals Inc.$183
  • Otsuka America Pharmaceutical, Inc.$162
  • Axsome Therapeutics, Inc.$157
  • plus $993 from 16 others

What the payments were for

  • Food & beverage$2,43698%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,483 in reported general payments places this provider in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$10,454
Medicare patients
32
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate27$230,441
Austedo XrDeutetrabenazine36$144,906
Invega SustennaPaliperidone Palmitate20$40,460
Abilify MaintenaAripiprazole14$35,715
VraylarCariprazine Hcl21$28,544
LybalviOlanzapine/Samidorphan Malate16$25,387
Lamotrigine ErLamotrigine38$12,904
TrintellixVortioxetine Hydrobromide13$8,038
Aripiprazole58$5,428
Eszopiclone18$2,424
Lurasidone Hcl14$2,004
Bupropion Hcl SrBupropion Hcl73$1,505
Buspirone Hcl127$1,220
Desvenlafaxine Succinate ErDesvenlafaxine Succinate30$1,198
Hydroxyzine Pamoate35$1,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$138$230,44127 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$93$144,90636 claims
Johnson & JohnsonInvega Sustenna$291$40,46020 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$162$35,71514 claims
AbbVieVraylar$383$28,54421 claims
Alkermes, Inc.Lybalvi$70$25,38716 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$60$8,03813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Richmond

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →